Guardant Health (GH) said Wednesday it introduced a full suite of immunohistochemistry, or IHC, testing for key biomarkers in all solid tumors, such as lung, breast, gastric and ovarian cancers.
The company said IHC testing detects tumor biomarkers that can be used to determine a tumor's characteristics and identify the most suitable targeted cancer treatment.
The new tests are now available in addition to the Guardant360 Tissue multiomic tumor profiling test, the company said.
Shares of Guardant Health were down more than 4% in recent trading.
Price: 38.19, Change: -1.78, Percent Change: -4.45
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。